A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)

NCT01358331 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor, Solid

Interventions

DRUG: MK-8353

Sponsor

Merck Sharp & Dohme LLC